Skip to main content

Table 4 Predictive performance of the PDPM models in predicting the disease progression in the cohorts

From: Baseline MRI-based radiomics model assisted predicting disease progression in nasopharyngeal carcinoma patients with complete response after treatment

Model

Training cohort (n = 119)

Validation cohort (n = 52)

AUC

95% CI

SEN

SPE

AUC

95% CI

SEN

SPE

Low

High

Low

High

L1

0.85

0.78

0.92

0.80

0.77

0.66

0.51

0.81

0.88

0.41

L2

0.69

0.59

0.78

0.75

0.54

0.66

0.50

0.81

0.44

0.89

L3

0.66

0.57

0.76

0.96

0.32

0.69

0.54

0.84

0.44

0.93

L4

0.75

0.66

0.83

0.67

0.75

0.77

0.64

0.90

0.92

0.52

S1

0.97

0.94

1.00

0.98

0.88

0.72

0.58

0.86

0.52

0.89

S2

0.84

0.76

0.91

0.84

0.72

0.61

0.45

0.77

0.80

0.44

S3

0.85

0.78

0.92

0.71

0.75

0.61

0.45

0.77

0.44

0.89

S4

0.95

0.91

0.98

0.96

0.78

0.67

0.52

0.82

0.64

0.63

  1. AUC, area under the curve; CI, confidence interval; SEN, sensitivity; SPE, specificity